Impact Biomedical INC Form 4 insider transactions

IMPACT BIOMEDICAL CFO Todd Macko sold 45,000 shares of common stock in late March 2026 under a Rule 10b5-1 trading plan.

IMPACT BIOMEDICAL Director Jason Grady sold 50,000 shares of common stock for $0.6501 per share on March 23, 2026.

DSS Inc. filed an amended Form 4 to correct its beneficial ownership of Impact Biomedical Inc. common stock following recent sales.

DSS, Inc., a 10% owner and director of IMPACT BIOMEDICAL INC., has reported the sale of its entire beneficial ownership of common stock in two transactions totaling 161,000 shares.

DSS, Inc. reports the sale of 890,800 shares of Impact Biomedical Inc. common stock on April 4, 2025.

Director Chan Heng Fai Ambrose reports the sale of 351,555 common stock shares of Impact Biomedical Inc. by Alset International Limited, a majority-owned subsidiary of Alset Inc.

Director and 10% owner Chan Heng Fai Ambrose, along with related entities Alset International Ltd. and Alset Inc., executed multiple sales of Impact Biomedical Inc. common stock between April 2 and April 4, 2025.

Alset International and Alset Inc., entities related to director Chan Heng Fai Ambrose, have sold a significant number of Impact Biomedical shares.

DSS, Inc. reports the sale of Impact Biomedical Inc. shares through multiple transactions, decreasing its direct and indirect holdings.

DSS, Inc. reports transactions involving Impact Biomedical Inc. (IBO) common stock, indicating changes in beneficial ownership.

Impact Biomedical's CEO, Frank D. Heuszel, purchased 500 shares of common stock at a price of $2.2578 per share.

Impact Biomedical's CEO, Frank D. Heuszel, purchased 500 shares of common stock at $2.61 per share on November 27, 2024.

Impact Biomedical's CEO, Frank D. Heuszel, has acquired 1,050 shares of common stock through open market purchases.

DSS, Inc. has reported the disposal of Impact Biomedical Inc. shares through a series of transactions, reducing its indirect holdings.

DSS, Inc. reports acquiring 1,000 shares of Impact Biomedical Inc. common stock at $2.33 per share.

DSS, Inc., a 10% owner of Impact Biomedical Inc., reports acquiring additional shares of common stock through indirect ownership.